Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy

The absence of reliable, robust, and non-invasive biomarkers for anti- Programmed cell death protein 1 (PD-1) immunotherapy is an urgent unmet medical need for the treatment of cancer patients. No predictive biomarkers have been established based on the direct assessment of T cell functions, the pri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences Jg. 21; H. 23; S. 9023
Hauptverfasser:	Bacot, Silvia M., Harper, Taylor A., Matthews, Rebecca L., Fennell, Christie Jane, Akue, Adovi, KuKuruga, Mark A., Lee, Shiowjen, Wang, Tao, Feldman, Gerald M.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 27.11.2020 MDPI
Schlagworte:	Antigens, CD - metabolism Biomarkers Biomarkers - metabolism Cancer Cell Proliferation - drug effects Cytokines Cytokines - biosynthesis Cytomegalovirus Deoxyribonucleic acid DNA FDA approval Flow cytometry Granzymes - metabolism Humans Immunoassay Immunotherapy Leukocytes, Mononuclear - metabolism Lymphocyte Activation - drug effects Lymphocytes Mutation Nivolumab - pharmacology Patients Programmed Cell Death 1 Receptor - metabolism T cell receptors T-Lymphocytes, Regulatory - drug effects T-Lymphocytes, Regulatory - immunology Targeted cancer therapy Th1 Cells - immunology Tissue Donors peripheral blood mononuclear cells cytokines T cells biomarker Nivolumab
ISSN:	1422-0067, 1661-6596, 1422-0067
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!